STAT3 Inhibition Attenuates MYC Expression by Modulating Co-Activator Recruitment and Suppresses Medulloblastoma Tumor Growth by Augmenting Cisplatin Efficacy In Vivo

Keyphrases

• Acetyltransferase p300 50%
• Adjuvant Therapy 50%
• Anti-apoptosis 50%
• Bromodomain-containing Protein 4 (BRD4) 50%
• Cancer Hallmarks 50%
• Central Nervous System 50%
• Chemoresistance 50%
• Chemosensitizer 50%
• Chemotherapy Toxicity 50%
• Childhood Malignancy 50%
• Cisplatin 100%
• Clinically Significant 50%
• Coactivator Recruitment 100%
• Efficacy in Vivo 100%
• H3K27 Acetylation 50%
• High Risk 100%
• Knockdown 50%
• Medulloblastoma 100%
• Molecular Subgroups 50%
• MYC Expression 100%
• MYC Oncogene 50%
• Occupancy 50%
• Orthotopic Xenograft 50%
• Pediatric Patients 50%
• Quality of Life 50%
• RNA Pol II 50%
• Small Molecule Inhibitors 50%
• STAT3 Inhibitor 100%
• STAT3 Signaling 50%
• Stemness 50%
• Therapy Resistance 50%
• Treatment Efficacy 50%
• Tumor 100%
• Tumor Growth 100%
• Worse Prognosis 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Childhood Cancer 50%
• Cisplatin 100%
• Combination Therapy 50%
• Drug Resistance 50%
• Histone Acetyltransferase 50%
• Malignant Neoplasm 50%
• Medulloblastoma 100%
• Mouse 50%
• Neoplasm 100%
• Therapy Resistance 50%
• Tumor Growth 100%

Biochemistry, Genetics and Molecular Biology

• Acetylation 16%
• BRD4 16%
• Bromodomain 16%
• Cisplatin 100%
• Drug Resistance 16%
• Genetics 16%
• Histone Acetyltransferase 16%
• Mouse 16%
• Oncogene 16%
• Promoter Region 16%
• RNA 16%
• Sensitization 16%
• Small Molecule 16%
• STAT3 100%
• Transcription 16%
• Tumor Progression 100%